Methods and apparatus for flow restoration

Information

  • Patent Grant
  • 8940003
  • Patent Number
    8,940,003
  • Date Filed
    Friday, February 20, 2009
    15 years ago
  • Date Issued
    Tuesday, January 27, 2015
    9 years ago
Abstract
Methods for restoring blood flow in occluded blood vessels using an apparatus having a self expandable distal segment that is pre-formed to assume a superimposed structure in an unconstrained condition but can be made to take on a volume-reduced form making it possible to introduce it with a microcatheter and a push wire arranged at the proximal end, with the distal segment in its superimposed structure assuming the form of a longitudinally open tube and having a mesh structure of interconnected strings or filaments or struts. In a preferred embodiment, the distal segment has a tapering structure at its proximal end where the strings or filaments or struts converge at a connection point.
Description
FIELD OF THE INVENTION

The present invention relates to methods and apparatus for quickly or immediately restoring blood flow in occluded blood vessels, particularly occluded cerebral arteries. Furthermore, the present invention relates to the application of such apparatus for thrombus removal and/or thrombus dissolution.


BACKGROUND OF THE INVENTION

Current technology for treating cerebral arteries occluded by thrombus may take hours to reestablish flow in the artery. Furthermore, known apparatus and methods for treating cerebral thrombus may be ineffective or only partially effective at resolving thrombus, and may additionally result in distal embolization or embolization of uninvolved arteries. The risk and degree of permanent neurological deficit increases rapidly with increased time from onset of symptoms to blood flow restoration.


SUMMARY OF THE INVENTION

The invention is directed to methods of restoring localized blood flow in a vascular site occluded with a thrombus. It is contemplated that the methods of the invention improve the speed and effectiveness of revascularization of cerebral arteries occluded by a thrombus.


In one embodiment, methods and apparatus are provided to create immediate (or restore) blood flow in the occluded artery upon deployment of the apparatus. In one aspect, a self-expandable apparatus is delivered to a site that is radially adjacent to the thrombus and the apparatus is expanded thereby restoring flow.


In another embodiment, the invention is directed to methods and apparatus that restore blood flow in the blood vessel that is occluded with a thrombus, with an associated increased efficiency in dislodging the thrombus from the vessel and removing the thrombus. In this embodiment, a self-expandable apparatus is delivered to a site that is radially adjacent to the thrombus and then expanded. The expanded apparatus then restores flow, which flow assists in dislodging the thrombus from the vessel wall. In one embodiment, the apparatus engages the thrombus and the thrombus can then be removed from the site of occlusion.


In yet another embodiment, the invention is directed to methods and apparatus that restore blood flow in the occluded artery, with an associated increased efficiency in dissolving part or all of the thrombus from the vessel and optionally retrieval of the apparatus. In this embodiment, a self-expandable apparatus is delivered to a site that is radially adjacent to the thrombus and then expanded. Once expanded, the apparatus then restores flow to the occluded site and this increased flow may dissolve or partially or substantially dissolve the thrombus and the apparatus-thrombus mass is then removed from the formerly occluded site.


In still yet another embodiment, the invention is directed to methods and apparatus that restore blood flow in the occluded artery, with an associated increased efficiency in dissolving part or all of the thrombus from the vessel and implantation of a portion of the apparatus. In this embodiment, the apparatus engages (or implants in or integrates with) at least a portion of the thrombus providing a removable, integrated apparatus-thrombus mass. The removable, integrated apparatus-thrombus is removed from the site of occlusion.


In some embodiments, the method of the invention is directed to a method for imaging restoration of blood flow in a blood vessel occluded with a thrombus. This method comprises: a) acquiring an image of a self-expandable apparatus placed radially adjacent to a thrombus; and b) acquiring an image of expanding the apparatus thereby restoring blood flow.


In another embodiment, the method of the invention is directed to a method for imaging partially or substantially dissolving a thrombus lodged in a blood vessel. This method comprises: a) acquiring an image of a self-expandable apparatus placed radially adjacent to a thrombus; and b) acquiring an image of expanding the apparatus thereby increasing blood through the vessel wherein the increased blood flow partially or substantially dissolves the thrombus.


In still yet another embodiment, the method of invention is directed to a method for imaging dislodging a thrombus lodged in a blood vessel. This method comprises:

  • a) acquiring an image of a self-expandable apparatus placed radially adjacent to a thrombus;
  • b) acquiring an image of expanding the apparatus thereby engaging at least a portion of the thrombus; and c) acquiring an image of moving the apparatus distally or proximally thereby dislodging the thrombus.


A number of self-expandable apparatus are contemplated to be useful in the methods of the invention. In one embodiment, the apparatus is reversibly self-expandable. In another embodiment, the apparatus is fully retrievable or retractable. In one embodiment, the self-expandable apparatus comprises a mesh structure comprising a first plurality of mesh cells, the mesh structure having a proximal end and a distal end; a tapering portion comprising a second plurality of mesh cells, the tapering portion disposed toward the proximal end of the mesh structure; and a connection point, at which the tapering portion converges, located at a proximal end of the tapering portion, wherein the apparatus is pre-formed to assume a volume-enlarged form and, in the volume-enlarged form, takes the form of a longitudinally open tube tapering toward the connection point.


Another embodiment of the invention is a self-expandable apparatus for removal of a thrombus in a blood vessel, comprising: a mesh structure comprising a first plurality of mesh cells, the mesh structure having a proximal end and a distal end wherein said distal end of the mesh structure is configured to engage at least a portion of the thrombus to form a removable, integrated apparatus-thrombus mass; a tapering portion comprising a second plurality of mesh cells, the tapering portion disposed toward the proximal end of the mesh structure; and a connection point, at which the tapering portion converges, located at a proximal end of the tapering portion, wherein the apparatus is pre-formed to assume a volume-enlarged form and, in the volume-enlarged form, takes the form of a longitudinally open tube tapering toward the connection point.


It is contemplated that the distal end of the mesh structure is configured to assist in thrombus retrieval by providing increasing support to the mesh structure and by increasing thrombus retention.


In another embodiment of the invention is provided a removable, integrated apparatus-thrombus mass, comprising a thrombus at least partially engaged with an apparatus, wherein the apparatus comprises a mesh structure comprising a first plurality of mesh cells, the mesh structure having a proximal end and a distal end wherein said distal end of the mesh structure is configured to engage at least a portion of the thrombus; a tapering portion comprising a second plurality of mesh cells, the tapering portion disposed toward the proximal end of the mesh structure; and a connection point, at which the tapering portion converges, located at a proximal end of the tapering portion, wherein the apparatus is pre-formed to assume a volume-enlarged form and, in the volume-enlarged form, takes the form of a longitudinally open tube tapering toward the connection point.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate exemplary embodiments of the invention, and, together with the general description given above and the detailed description given below, serve to explain the features of the invention.



FIG. 1 shows an apparatus useful for the methods of the present invention.



FIG. 2
a shows a target occlusion or thrombus to be treated by the present invention.



FIGS. 2
b, 3, and 4 show placement methods according to the present invention. FIG. 3 is shown with the microcatheter 8 in phantom.



FIG. 5 shows thrombus dislodgement and mobilization according to the present invention.



FIGS. 6 and 7 show thrombus dissolution methods according to the present invention.



FIGS. 8 and 9 show apparatus retrieval methods according to the present invention, with the microcatheter shown in phantom.



FIGS. 10, 11, and 12 show apparatus implantation methods according to the present invention.



FIG. 13 is an apparatus according to one embodiment of the present invention having a honeycomb structure.



FIG. 14 is another embodiment of a stent according to the present invention having a honeycomb structure.



FIG. 15 is a third embodiment of a stent according to the present invention having a honeycomb structure.



FIG. 16 is a warp-knitted structure as can be used for an apparatus according to the invention.



FIG. 17
a and FIG. 17b is a schematic representation of an apparatus according to an embodiment of the present invention shown in its superimposed and in its volume-reduced shape.



FIG. 18
a, FIG. 18b, FIG. 18c, FIG. 18d, and FIG. 18e are embodiments, including marker elements, that can be employed in the most distal segment of the apparatus according to the present invention.



FIG. 19
a and FIG. 19b are schematic representations of two detachment locations by which the apparatus, according to the present invention, can be detachably linked to a guide wire.





DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications and patent applications cited herein are incorporated herein by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.


It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.


Methods

The invention is directed to methods of restoring localized flow to an occluded vascular site. The vascular site, or blood vessel, can be occluded by a thrombus. The apparatus employed in the methods of the invention may be positioned at the vascular site with a microcatheter and optionally a guide catheter. The methods of the invention may employ a fully retrievable apparatus which is an improvement over the art which methods required the apparatus to be implanted permanently into the patient. When the apparatus is permanently placed in the patient, lifelong anticoagulant therapy for the patient is required. Therefore, it is contemplated that by using a retrievable apparatus, lifelong anticoagulant therapy may be avoided.


Methods and apparatus are provided to restore blood flow in cerebral arteries 11 occluded with thrombus 12 (FIG. 2a). Such methods utilize an apparatus having a self-expandable, optionally reversibly self-expandable, distal segment 1 including distal end 2, proximal end 3, and body portion 4 that is pre-formed to assume a superimposed structure 5 in an unconstrained condition but can be made to take on a volume-reduced form 6 making it possible to introduce it with a push wire 7 attached at the proximal end 3 and a microcatheter 8, with the distal segment 1 in its superimposed structure 5 assuming the form of a longitudinally open tube and having a mesh structure of interconnected strings or filaments or struts (FIGS. 1 and 3). In one embodiment, the distal segment 1 has a tapering structure at its proximal end 3 where the strings or filaments or struts converge at a connection point 9. The push wire 7 is preferably attached at or adjacent to the connection point 9. Such attachment 10 may be permanent or a releasable mechanism. The methods disclosed herein can be performed with the medical distal segment 1 (or apparatus or stent, of which all terms are used interchangeably) described in U.S. Pat. No. 7,300,458, which is incorporated herein in its entirety.


According to the present invention, the self-expandable distal segment 1 of the apparatus is positioned within a blood vessel 11 occluded by thrombus 12 in a volume-reduced form 6 by advancing it with the push wire 7 within a microcatheter 8 such that its proximal end 3 is upstream of the thrombus and its distal end 2 and is downstream of the thrombus and the body portion 4 is located radially adjacent to the thrombus 12 (FIGS. 1 and 3). As shown in FIG. 3, the distal end 2 of the distal segment 1 is positioned distal to the distal thrombus boundary and the proximal end 3 of the distal segment is positioned proximal of the proximal thrombus boundary. The distal segment 1 is held in a fixed position by holding the push wire 7 stationary while the distal segment 1 is released from its volume-reduced form 6 by withdrawing the microcatheter 8 proximally of the distal segment 1 (FIG. 4). The distal segment 1 assumes at least a portion of its superimposed structure 5 in its unconstrained condition 13 thereby expanding to bring at least part of the body portion into penetrating contact with the thrombus 12′, exerting an outward radial force on the thrombus 12′, reducing the cross-sectional area of the thrombus 12′, and immediately re-establishing blood flow 14 through the blood vessel 11 past the thrombus 12′.


Also contemplated by this invention is administration of an effective amount of a clot-busting drug, such as, for example tissue plasminogen activator (tPA), to the site of the thrombus. Administration of this drug will act to further enhance dissolution of the clot.


This placement methodology expands the population of patients eligible for treatment over apparatus that require intravascular space distal to the reach of a microcatheter as the methodology of this invention places the distal segment 1 beyond the distal end of the thrombus 12. Additionally, this placement methodology expands the population of physicians that can successfully practice the method, as it is delivered with microcatheter technology already familiar to the user, and facilitates rapid placement of the apparatus. Immediately restoring blood flow 14 is a significant advantage over known apparatus and methods for treating cerebral arteries 11 occluded by thrombus 12 because known apparatus and methods may take hours to re-establish flow 14, and it is well established that the risk and degree of permanent neurological deficit increases rapidly with increased time from onset of symptoms to blood flow restoration.


In one embodiment thrombus removal methods and apparatus are provided that restore blood flow 14 in the occluded artery 11, with an increased efficiency in dislodging the thrombus 12′ from the vessel coupled with removal of the thrombus 12′ and apparatus from the patient. In a preferred embodiment, restoring blood flow 14 in the occluded artery 11 involves placing a microcatheter 8 such that the distal tip 16 of the microcatheter is beyond the distal end of the thrombus 12, wherein the distal tip 16 is from greater than about 0 millimeter (mm) to about 10 mm or more, or about 3 mm to about 5 mm (FIG. 2b) beyond the distal end of the thrombus 12. The self-expandable distal segment 1 is advanced within the microcatheter 8 in its reduced volume form 6 by the push wire 7 until its distal end 2 is just beyond the distal end of the thrombus 12 (FIG. 3).


Visualization of proper placement may be done by fluoroscopy. Specifically, this may be accomplished by aligning radiopaque markers 15 on the distal end of the distal segment with a distal radiopaque microcatheter marker 17 (FIG. 3). As mentioned above, this invention is also directed to various methods of acquiring images of the process. The method of imaging typically employed is fluoroscopy (which can confirm proper placement of the apparatus) or contrast injection (which can confirm blood flow restoration). However, a number of imaging methods known by those of skill in the art are also contemplated.


The distal segment 1 is then deployed within and across the thrombus 12′ by holding the push wire 7 fixed while withdrawing the microcatheter 8 proximally until the distal segment 1 is released 13 (FIG. 4). One indication of full deployment is the visualization by the clinician that a radiopaque marker 18 defining the proximal end 3 of the distal segment 1 is aligned with, or distal of, the distal radiopaque microcatheter marker 17. Alternatively, the microcatheter 8 can be completely removed from the patient. Immediately upon distal segment 1 deployment 13, blood flow 14 is restored across the thrombus 12′ and confirmation can be visualized via contrast injection. This is an indication of proper distal segment position relative to the thrombus 12′ and vascular anatomy.


The apparatus can be used to remove the thrombus 12′ after one of the following: a fixed amount of time has elapsed after deployment 13 of the distal segment 1, which may be from about 0 minutes to about 120 minutes or more; blood flow 14 across the thrombus 12′ is observed to stop; a predetermined maximum amount of flow time has elapsed, whichever occurs first.


Removing the thrombus 12′ may be accomplished by any number of variations (FIG. 5). For example, as the distal tip of volume-reduced form 6 is moved beyond the thrombus, it will encounter less resistance to expansion and provide a greater radial force as compared to that portion engaging the thrombus as shown in FIG. 5. Thus distal tip 2 may expand beyond the thrombus 12′ creating a distal tip 2 having a larger diameter than the diameter of the distal segment that is engaged by at least a portion of the thrombus. In some embodiments, this can be a hook-like distal configuration. Further structural modifications are described below that could be used to further aid in thrombus engagement and removal. Using the push wire 7, a pull force 19 of the deployed distal segment 13 will retract the thrombus back to the catheter as the hook-like configuration acts to snag the thrombus. Subsequent removal of the catheter will result in removal of the thrombus from the site of occlusion.


Prior to pulling the apparatus back, the microcatheter 8 can be manipulated in any of the following ways: the distal radiopaque microcatheter marker 17 can be left at or proximal to distal segment proximal radiopaque marker 18 or completely removed from patient; microcatheter 8 can be moved forward to a predetermined point relative to the distal segment 1, which may be: when the distal radiopaque microcatheter marker 17 is desirably aligned with the distal segment of proximal radiopaque marker 18; when the distal radiopaque microcatheter marker 17 is desirably aligned distal of the distal segment of proximal radiopaque marker 18, for example about 0.5 mm to about 10 mm or about 5 mm to about 10 mm; when significant resistance to microcatheter 8 advancement is encountered as evidenced by buckling of the microcatheter 8; or whichever of desired-alignment or significant resistance occurs first. While moving the deployed distal segment 13 toward or into the guide catheter, any of the following may occur: proximal guide lumen communicates with pressure bag or other positive pressure fluid source; proximal guide lumen communicates with atmosphere; or proximal guide lumen communicates with aspiration source or other negative pressure.


Thrombus removal methods of the present invention have unique advantages over known thrombus removal methods. When deployed across a thrombus, the distal segment 1 creates intra-procedural flow 14 by creating a fluid path across the thrombus 12′ (FIG. 4). In this way, the distal segment 13 significantly reduces the pressure drop across the thrombus 12′, and accordingly significantly reduces the pressure related forces which would otherwise resist removal of the thrombus 12 (FIG. 5). Further, the fluid path is created by the deployed distal segment 13 separating a significant portion of the thrombus 12′ circumference away from the vessel wall. In addition, expansion of volume-reduced form 6 creates an integrated mass where the mesh is embedded within the thrombus. As above, the distal portion of volume-reduced form 6 can produce a greater radial force (and may be in a hook-like configuration upon expansion) thereby facilitating removal of the thrombus.


It is estimated that about 10% to about 60% of the original thrombus 12 circumference is separated from the vessel wall after the distal segment 1 is deployed 13, and the ability of the post deployment thrombus 12′ to hang onto the vessel wall via adhesion and friction is accordingly reduced. Still further, the cross sectional area of the original thrombus 12 is significantly reduced by the deployed distal segment 13, resulting in a thrombus 12′ having about 30% to about 95% of its original cross sectional area, but more typically about 50% to about 80% of its original cross sectional area. All of this results in a more effective revascularization procedure as a result of lower thrombus dislodgement and mobilization force and more effective thrombus mobilization 19, as demonstrated by the functions later described herein. Of further benefit, the lower thrombus mobilization force is distributed along the entire length of the thrombus 12′, or at least along the entire length of the distal segment 13, reducing the chances of the apparatus slipping past or through the thrombus or fragmenting the thrombus, which could result in residual thrombus, distal embolization, or embolization of uninvolved territories.


A target occlusion is represented by an original thrombus 12 having cross sectional area A (FIG. 2a), creating an associated pressure drop across the thrombus of P, having circumferential vessel contact area C, and f is a quantity proportional to a ratio of the thrombus adhesive and frictional forces/contact area. The force required to dislodge or mobilize this thrombus by known methods that do not establish intra-procedural flow across the thrombus and do not separate a significant portion of the thrombus circumference away from the vessel wall can be described by the function:

(A*P)+C*f


For the thrombus removal methods of the present invention, that is when the distal segment 1 is deployed 13 within the thrombus 12′ (FIG. 4), the thrombus 12′ has reduced cross sectional area “a” where a<A, reduced pressure drop across the thrombus “p” where p<P, significantly reduced circumferential vessel contact area “c” where c<C, and f is a quantity proportional to a ratio of the thrombus adhesive and frictional forces/contact area. The force required to dislodge and mobilize the thrombus 12′ according to the methods described herein will be significantly lower than forces required to dislodge and mobilized original thrombus 12 by known methods (FIG. 5), and can be described by the function:

(a*p)+c*f


Also contemplated by the present invention are thrombus dissolution methods and apparatus that restore blood flow 14 in the occluded artery, with an increased efficiency in dissolving part (FIG. 7) or all (FIG. 6) of the thrombus from the vessel and retrieval of the apparatus (FIGS. 8 and 9). As previously described, the distal segment is deployed within and across a thrombus 12′ to restore blood flow 14 in the occluded artery (FIG. 4). Immediately reestablishing blood flow 14 is a significant advantage over know apparatus and methods for treating cerebral arteries occluded by thrombus because known apparatus and methods may take hours to reestablish flow. Specific benefits include reestablishing antegrade flow distal of the original occlusion to perfuse ischemic tissue and help break up emboli that may be present distal of the original occlusion. Additional benefit is derived from increasing the surface area of the thrombus 12′ exposed to the blood flow, thereby improving the effectivity of natural lysing action of the blood on the thrombus 12′ and improving the effectivity of the thrombolytic, anti-coagulant, anti-platelet, or other pharmacological agents introduced by the physician, all of which facilitates thrombus dissolution. When the thrombus has been completely dissolved (FIG. 6), or sufficiently reduced 12″ such that reocclusion is not likely (FIG. 7), the distal segment 1 is retrieved 20 by advancing the microcatheter 8 over the entire distal segment 1 while holding the push wire 7 in a fixed position such that the distal segment 1 is not moved axially within the artery (FIGS. 8 and 9). The apparatus may then be removed through the microcatheter 8 or alternatively the microcatheter 8 can be removed with the distal segment 1 of the apparatus still inside of it.


Additionally, it is contemplated that the methods of the present invention can restore blood flow in the occluded artery, with an increased efficiency in dissolving part or all of the thrombus from the vessel and implantation of the distal segment 1. Methods that include implantation of the distal segment 1 require the use of an apparatus with a releasable attachment mechanism between the distal segment 1 and push wire 7. As previously described, the distal segment 1 is deployed within and across 13 a thrombus 12′ to restore blood flow 14 in the occluded artery (FIG. 4). The distal segment 1 can then be released from the push wire via a releasable attachment mechanism. Such release may occur immediately upon reestablishing blood flow (FIG. 10), when the thrombus 12″ has been sufficiently reduced such that reocclusion is not likely (FIG. 11), or when the thrombus is completely dissolved (FIG. 12).


In another embodiment of the invention, the thrombus removal or dissolution is assisted by aspirating the microcatheter and/or the guide catheter.


Utility derived from a releasable mechanism between the distal segment and push wire includes suitability of one apparatus for all of the methods disclosed herein, providing procedural options for the user. Of further benefit, a releasable mechanism enables the user to release the unconstrained distal segment if it is determined that removal from the patient is not possible.


Certain embodiments of the invention include methods of restoring blood flow and then detaching the apparatus and leaving the apparatus in situ (FIG. 12). This can be done when it is determined by the clinician that either the apparatus is no longer retrievable. In this embodiment, it is contemplated that the apparatus would be coated or otherwise embedded with anticoagulant or antiplatelet drugs. This is more thoroughly discussed below.


Apparatus

As mentioned above, any suitable self-expandable apparatus may be employed by the methods of the invention. Various embodiments of the apparatus may be found in U.S. Pat. No. 7,300,458, which is incorporated by reference in its entirety.


A distal segment 1, according to FIG. 13, consists of a mesh or honeycomb structure that, in one embodiment, comprises a multitude of filaments interconnected by a laser welding technique. The distal segment 1 can be subdivided into a functional structure A and a tapering proximal structure B, the two structures being distinguishable, inter alia, by a different mesh size. To enable the functional structure A to perform its function, its mesh cells 23 are held relatively narrow so that they lend themselves to the implantation into the thrombus 12. In general, the mesh width is in the range of 0.5 to 4 mm and may vary within the segment.


In one aspect of the present invention, the distal segment 1 is a flat or two-dimensional structure that is rolled up to form a longitudinally open object capable of establishing close contact with the wall of the vessel into which it is introduced.


In the tapering proximal structure B of the distal segment 1, there is provided a wider mesh cell 24 structure which has been optimized towards having a minimum expansion effect. In the area of the tapering structure 22, the filaments have a greater thickness and/or width to be able to better transfer to the functional structure A the thrust and tensile forces of the guide wire exerted at a connection point 9 when the distal segment 1 is introduced and placed in position. In the area of the tapering structure it is normally not necessary to provide support for, and coverage of, the vessel wall, but on the other hand requirements as to tensile and thrust strength increase. The filament thickness in the functional structure A generally ranges between 0.02 and 0.076 mm, and in proximal structure part B, the filament thickness is greater than 0.076 mm.


The proximal structure forms an angle from 45 degrees to 120 degrees at the connection point 9, in particular an angle of about 90 degrees. The filament thickness (or string width) is the same as the mesh size and its shape may vary over a great range to suit varying requirements as to stability, flexibility and the like. It is understood that the proximal structure B, as well, contacts the vessel wall and thus does not interfere with the flow of blood within the vessel.


At a distal end, the filaments 22 end in a series of tails 2 that are of suitable kind to carry platinum markers that facilitate the positioning of the distal segment 1.


The distal segment 1 is curled up in such a way that edges 27 and 28 are at least closely positioned to each other and may overlap in the area of the edges. In this volume-reduced form, the distal segment 1, similar to a wire mesh roll, has curled up to such an extent that the roll so formed can be introduced into a microcatheter and moved within the catheter. Having been released from the microcatheter, the curled-up structure springs open and attempts to assume the superimposed structure previously impressed on it and in doing so closely leans to the inner wall of the vessel to be treated, thus superficially covering a thrombus and then implanting into the thrombus that exists in that location. In this case the extent of the “curl up” is governed by the vessel volume. In narrower vessels a greater overlap of the edges 27 and 28 of the distal segment 1 will occur whereas in wider vessels the overlap will be smaller or even “underlap,” will be encountered, and due care must be exercised to make sure the distal segment 1 still exhibits a residual tension.


Suitable materials that can be employed in the device include alloys having shape-memory properties. The finished product is subjected to a tempering treatment at temperatures customarily applied to the material so that the impressed structure is permanently established.


The distal segment 1 has a mesh-like structure consisting of strings or filaments connected with each other. Strings occur if the distal segment 1 comprises cut structures as, for example, are frequently put to use in coronary stents, a mesh-like structure consisting of filaments is found if the distal segment 1 is present in the form of mats having knitted or braided structures or in the form of individual filaments that are welded to one another.



FIG. 14 shows another embodiment of a distal segment 1 according to the invention having the above described honeycomb structure where the tapering proximal structure B is connected with the functional structure part A by additional filaments 29 in a peripheral area 30 as well as in the central area. The additional filaments 29 and 30 bring about a more uniform transmission of the tensile and thrust forces from the proximal structure B to the functional structure A. As a result, the tensile forces can be better transmitted, especially if the stent might have to be repositioned by having to be retracted into the microcatheter. The additional filaments 29, 30 facilitate the renewed curling up of the stent. Similarly, the transmission of thrust forces occurring when the stent is moved out and placed in position is facilitated so that the stent can be gently applied.



FIG. 15 shows another embodiment of a distal segment 1 according to the invention having a honeycomb structure with the edges 27 and 28 being formed of straight filaments 29. According to this embodiment, the thrust or pressure exerted by the guide wire at the connection point 9 is directly transmitted to the edges 27 and 28 of the functional structure part A which further increases the effect described with reference to FIG. 14.


The embodiment as per FIG. 15, similar to those depicted in FIGS. 13 and 14, may be based on a cut foil, i.e., the individual filaments 22, 29 and 30 are substituted by individual strings being the remaining elements of a foil processed with the help of a cutting technique. Laser cutting techniques for the production of stents having a tubular structure are known. The processing of a foil for the production of a pattern suitable for a stent is performed analogously. The impression of the superimposed structure is carried out in the same way as is used for the filament design.


In one embodiment, expanded metal foil may be used with the respective string widths being of the same magnitude. In one embodiment, it is envisioned to subsequently smooth the foil to make sure all strings are arranged on the same plane. The thickness of the foil usually ranges between 0.02 and 0.2 mm. Foils of greater thickness also permit the stent to be used in other fields of application, for example, as coronary stents or in other regions of the body including, for instance, the bile duct or ureter.


Foils worked with the help of a cutting technique are finished by electrochemical means to eliminate burrs and other irregularities to achieve a smooth surface and round edges. One of ordinary skill in the art will understand these electrochemical processes as these processes already are in use in medical technology. In this context, it is to be noted that the stents according to the invention that are based on a two-dimensional geometry and on which a three-dimensional structure is impressed subsequently can be manufactured and processed more easily than the conventional “tubular” stents that already, during manufacture, have a three-dimensional structure and necessitate sophisticated and costly working processes and equipment.


As pointed out above, the mesh structure of the distal segment 1 according to the invention may consist of a braiding of individual filaments. Such a knitted structure is shown in FIG. 16 where the individual filaments 22 are interwoven in the form of a “single jersey fabric” having individual loops 23 forming a mesh-like structure 31. Single jersey goods of this type are produced in a known manner from a row of needles. The single jersey goods have two fabric sides of different appearance, i.e., the right and left side of the stitches. A single jersey fabric material features minor flexibility in a transverse direction and is very light.


Filaments consisting of a braid of individual strands and formed into a rope can also be employed. Braids comprising twelve to fourteen strands having a total thickness of 0.02 mm can be used. Platinum, platinum alloys, gold and stainless steel can be used as materials for the filaments. Generally speaking, all permanent distal segment 1 materials known in medical technology can be employed that satisfy the relevant requirements.


In one embodiment, it is advantageous to have the fabric rims of such a knitted structure curling up as is known, for example, from the so-called “Fluse” fabric, a German term, which is of benefit with respect to the superimposed structure and application dealt with here. In this case, the superimposed structure can be impressed by means of the knitting process. However, the use of shape-memory alloys in this case as well is feasible and useful.


For the production of such knitted structures, known knitting processes and techniques can be employed. However, since the distal segments according to the invention are of extremely small size—for example, a size of 2 by 1 cm—it has turned out to be beneficial to produce the distal segments in the framework of a conventional warp or weft knitting fabric of textile, non-metallic filaments, for example, in the form of a rim consisting of the respective metallic filaments from which the weft or warp knitting fabric either starts out or that extends from such a fabric. The arrangement of the metallic part of the weft or warp knitting fabric at the rim achieves the aforementioned curling effect. The non-metallic portions of the knitted fabric are finally removed by incineration, chemical destruction or dissolution using suitable solvents.



FIG. 1 shows a combination of a guide wire 7 with the distal segment 1 attached to it that consists of filaments connected to each other by welding. The distal ends 2 and the connection point 9 where the filaments of the distal segment 1 converge in a tapering structure and that simultaneously represents the joining location with guide wire 7 are shown. The guide wire 7 is introduced into a microcatheter 8 which is of customary make.


Shifting the guide wire 7 within the catheter 8 will cause the distal segment 1 to be pushed out of or drawn into the catheter. Upon the stent being pushed out of the microcatheter 8 the mesh-like structure attempts to assume the superimposed shape impressed on it, and when being drawn in, the mesh structure folds back into the microcatheter 8 adapting to the space available inside.


As a result of the stiffness of its mesh structure, the distal segment 1 can be moved to and fro virtually without restriction via the guide wire 7 until it has been optimally positioned within the vessel system.


As mentioned earlier, customary microcatheters can be used. One advantage of the distal segment 1 according to the invention and of the combination of distal segment 1 and guide wire according to the invention is, however, that after having placed the microcatheter in position with a customary guide wire/marker system, the combination of guide wire 7 and distal segment 1 according to the invention can be introduced into the microcatheter, moved through it towards the implantation site and then moved out and applied in that position. Alternatively, it will be possible to have a second microcatheter of smaller caliber accommodate guide wire 7 and distal segment 1 and with this second microcatheter within the firstly positioned microcatheter shift them to the implantation site. In any case, the distal segment 1 can be easily guided in both directions.



FIG. 17 shows a schematic representation of an distal segment 1 according to the invention in its superimposed or volume-expanded shape and in its volume-reduced shape. In its expanded shape, as illustrated in FIG. 17a, the distal segment 1 forms a ring-shaped structure with slightly overlapping edges 27 and 28. In FIG. 17a the distal segment 1 is viewed from its proximal end as a top view with the connection point 9 being approximately positioned opposite to the edges 27 and 28. In the combination according to the invention, the guide wire 7 is affixed at the connection point 9.



FIG. 17
b shows the same distal segment 1 in its volume-reduced form 6 as it is arranged, for example, in a microcatheter in a curled up condition. In the case illustrated there is a total of two windings of the curled-up distal segment 1 with the connection point 9 being located at the proximal side and the two lateral edges 27 and 28 being the starting and final points of the roll or spiral. The structure is held in its volume-reduced form by the microcatheter 8 and when the distal segment 1 is pushed out of the microcatheter 8 it springs into its expanded shape, as illustrated by FIG. 17a, similar to a spiral spring.



FIG. 18
a shows a marker element 15 suitable for the distal segment 1 according to the invention with the marker element 15 being capable of being arranged at the distal end of the distal segment 1. The marker element 15 consists of a lug 33 provided with a small marker plate 35 levelly arranged inside it, i.e., flush with the plane of the distal segment 1 without any projecting elements. The plate 35 is made of an X-ray reflecting material, for example, platinum or platinum-iridium. The marker plate 35 may be connected to the surrounding distal segment 1 structure by known laser welding techniques. As shown in FIG. 18b, the marker elements 15 are arranged at the distal end of the distal segment 1.


As mentioned above, in one embodiment, the apparatus is configured to so as to provided a removable, integrated thrombus apparatus-mass. This configuration can be done in a variety of ways. For example, as can be seen in FIG. 18c, marker element 15′ can be provided in a spiral thereby increasing the support of the distal end of the mesh structure and aiding in the thrombus retrieval. Also, as seen in FIG. 18d, the marker element 15″ can be provided as an eyelet shape functioning in a manner similar to the spiral marker 15′. FIG. 18e shows a marker element 15′″ shown in the shape of a hook or a peg which can be added to provide additional retention of the thrombus during removal. Marker element 15′″ is optionally radiopaque or may be made from the same shape memory alloy as the mesh structure.


Additional structural configurations contemplated to provide a removal, integrated thrombus apparatus-mass include: 1) a greater diameter of the mesh structure in the most distal location of the distal segment 1 compared to the proximal end of the mesh structure (or a widening-taper on the distal end of the distal segment 1); 2) a third plurality of mesh cells located in the most distally in the distal segment 1, wherein the this third plurality of mesh cells have smaller mesh size compared to the first plurality of mesh cells; 3) adding synthetic polymers or polymeric fibers to the mesh structure; and 4) heating the distal end of the distal segment 1 for a time sufficient to impart increased radial strength for better thrombus retention.


As mentioned above, fibers may be added to the mesh structure. Fibers may be wrapped or wound around the mesh structure. They may have loose ends or may be fully braided throughout the distal segment 1.


Suitable fibers are taught in US Publication 2006/0036281, which is incorporated by reference in its entirety. In certain embodiments, the fibers may be comprised of polymeric materials. The polymeric materials may include materials approved for use as implants in the body or which could be so approved. They may be nonbiodegradable polymers such as polyethylene, polyacrylics, polypropylene, polyvinylchloride, polyamides such as nylon, e.g., Nylon 6.6, polyurethanes, polyvinylpyrrolidone, polyvinyl alcohols, polyvinylacetate, cellulose acetate, polystyrene, polytetrafluoroethylene, polyesters such as polyethylene terephthalate (Dacron), silk, cotton, and the like. In certain specific embodiments the nonbiodegradable materials for the polymer component may comprise polyesters, polyethers, polyamides and polyfluorocarbons.


The polymers can be biodegradable as well. Representative biodegradable polymers include: polyglycolic acid/polylactic acid (PGLA), polycaprolactone (PCL), polyhydroxybutyrate valerate (PHBV), polyorthoester (POE), polyethyleneoxide/polybutylene terephthalate (PEO/PBTP), polylactic acid (PLA), polyglycolic acid (PGA), poly (p-dioxanone), poly (valetolactone), poly (tartronic acid), poly (β malonic acid), poly (propylene fumarate), poly (anhydrides); and tyrosine-based polycarbonates. Additional polymers contemplated include polyglycolide and poly-L-lactide.


Other equivalent materials, including but not limited to stereoisomers of any of the aforementioned, may be used as well.



FIGS. 19
a and 19b are representations, respectively, of two variations of a separating arrangement by which the distal segment 1 according to the invention is detachably connected to a guide wire 7. In each case, a separating arrangement consists of a dumb-bell shaped element 43 that dissolves under the influence of electrical energy when in contact with an electrolyte. At the proximal (guidewire side) end of the dumb-bell shaped separating element 43, as per FIG. 19a, a spiral structure 45 is located that interacts with a strengthening spiral 46 of the guide wire 7. At the distal end, a ball-shaped element 47 is arranged that, with the help of a laser welding technique, is connected to a platinum spiral 48 which, in turn, is linked with the connection point 9 situated at the proximal end of the distal segment 1. The platinum spiral 48 also serves as an X-ray reflecting proximal marker of the distal segment 1.


To strengthen the joint between the ball-shaped element 47 and the connection point 9, a reinforcement wire 49 may be provided. Alternatively, the platinum spiral 48 may also be designed in such a manner that it withstands the tensile and thrust forces imposed on it.


The separating element 43 can include a steel material that is susceptible to corrosion in an electrolyte under the influence of electrical energy. To accelerate corrosion and shorten the separating time span, a structural or chemical weakening of the dumb-bell shaped element 43 may be beneficial, for example, by applying grinding methods or thermal treatment.


Generally, the portion of the dumb-bell 43 accessible to the electrolyte has a length of 0.1 to 0.5 mm, particularly 0.3 mm.


The spiral structure 45 is secured via welding both to the dumb-bell shaped element 43 and the reinforcement spiral 46 of the guide wire 7. The guide wire 7 itself is slidably accommodated within the microcatheter 8.



FIG. 19
b shows a second embodiment that differs from the one described with respect to FIG. 19a, in that the dumb-bell shaped element 43 has a ball-shaped element 47 at each end. The ball shaped elements 47 are connected distally to the connection point 9 of the distal segment 1 and proximally to the guide wire 7 via spirals 48, 46, respectively.


It is of course also provided that other separating principles may be applied, for example, those that are based on mechanical principles or melting off plastic connecting elements.


Coated Apparatus

This invention also contemplates coating the apparatus with anticoagulant and/or an antiplatelet agent or drug. It is contemplated that a drug may be used alone or in combination with another drug.


Anticoagulant agents or anticoagulants are agents that prevent blood clot formation. Examples of anticoagulant agents include, but are not limited to, specific inhibitors of thrombin, factor IXa, factor Xa, factor XI, factor XIa, factor XIIa or factor VIIa, heparin and derivatives, vitamin K antagonists, and anti-tissue factor antibodies, as well as inhibitors of P-selectin and PSGL-1. Examples of specific inhibitors of thrombin include hirudin, bivalirudin (Angiomax®), argatroban, ximelagatran (Exanta®), dabigatran, and lepirudin (Refludan®). Examples of heparin and derivatives include unfractionated heparin (UFH), low molecular weight heparin (LMWH), such as enoxaparin (Lovenox®), dalteparin (Fragmin®), and danaparoid (Orgaran®); and synthetic pentasaccharide, such as fondaparinux (Arixtra®), idraparinux and biotinylated idraparinux. Examples of vitamin K antagonists include warfarin (Coumadin®), phenocoumarol, acenocoumarol (Sintrom®), clorindione, dicumarol, diphenadione, ethyl biscoumacetate, phenprocoumon, phenindione, and tioclomarol.


Antiplatelet agents or platelet inhibitors are agents that block the formation of blood clots by preventing the aggregation of platelets. There are several classes of antiplatelet agents based on their activities, including, GP IIb/IIIa antagonists, such as abciximab (ReoPro®), eptifibatide (Integrilin®), and tirofiban (Aggrastat®); P2Y12 receptor antagonists, such as clopidogrel (Plavix®), ticlopidine (Ticlid®), cangrelor, ticagrelor, and prasugrel; phosphodiesterase III (PDE III) inhibitors, such as cilostazol (Pletal®), dipyridamole (Persantine®) and Aggrenox® (aspirin/extended-release dipyridamole); thromboxane synthase inhibitors, such as furegrelate, ozagrel, ridogrel and isbogrel; thromboxane A2 receptor antagonists (TP antagonist), such as ifetroban, ramatroban, terbogrel, (3-{6-[(4-chlorophenylsulfonyl)amino]-2-methyl-5,6,7,8-tetrahydronaphth-1-yl}propionic acid (also known as Servier S 18886, by de Recherches Internationales Servier, Courbevoie, France); thrombin receptor antagonists, such as SCH530348 (having the chemical name of ethyl (1R,3aR,4aR,6R,8aR,9S,9aS)-9-(E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-C]furan-6-ylcarbamate, by Schering Plough Corp., New Jersey, USA, described in US2004/0192753A1 and US2004/0176418A1 and studied in clinical trials, such as A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention with ClinicalTrials.gov Identifier: NCT00132912); P-selectin inhibitors, such as 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (also known as PSI-697, by Wyeth, N.J., USA); and non-steroidal anti-inflammatory drugs (NSAIDS), such as acetylsalicylic acid (Aspirin®), resveratrol, ibuprofen (Advil®, Motrin®), naproxen (Aleve®, Naprosyn®), sulindac (Clinoril®), indomethacin (Indocin®), mefenamate, droxicam, diclofenac (Cataflam®, Voltaren®), sulfinpyrazone (Anturane®), and piroxicam (Feldene®). Among the NSAIDS, acetylsalicylic acid (ASA), resveratrol and piroxicam are preferred. Some NSAIDS inhibit both cyclooxygenase-1 (cox-1) and cyclooxygenase-2 (cox-2), such as aspirin and ibuprofen. Some selectively inhibit cox-1, such as resveratrol, which is a reversible cox-1 inhibitor that only weakly inhibits cox-2.


In one embodiment, a controlled delivery of the drug can control the lytic effect of the drug and treat ischemic stroke and many other vascular diseases. The release rate can be controlled such that about 50% of the drug can be delivered to the thrombus in from about 1 to about 120 minutes. This controlled delivery can be accomplished in one or more of the following ways. First, the drug and polymer mixture may be applied to the stent and the amount of polymer may be increased or the combination may be applied in a thicker layer. Second, the stent may be first coated with polymer, then coated with a layer of drug and polymer, and then a topcoat of polymer can be applied. The release rates of the drug can be altered by adjusting the thickness of each of the layers. Third, the stent can be manufactured to provide reservoirs to hold the drug. In this embodiment, the drug is filled in small reservoirs made on the stent surface. Reservoirs can be made by laser cutting, machine electro-chemical, mechanical or chemical processing.


In the embodiments just described the polymer is biocompatible and biodegradable. These polymers are well known in the art.


Additionally, stents can be coated with a drug-eluting coating such as a combination of a polymer and a pharmaceutical agent. Such coatings can be applied using methods well established in the art, such as dipping, spraying, painting, and brushing. See, U.S. Pat. Nos. 6,214,115; 6,153,252; U.S. Patent Application No. 2002/0082679; U.S. Pat. Nos. 6,306,166; 6,517,889; 6,358,556; 7,318,945; 7,438,925.


For example, Chudzik et al. (U.S. Pat. No. 6,344,035) teaches a method wherein a pharmaceutical agent or drug is applied in combination with a mixture of polymers such as poly(butyl methacrylate) and poly(ethylene-co-vinyl acetate). Guruwaiya et al. discloses a method for coating a stent wherein a pharmacological agent is applied to a stent in dry, micronized form over a sticky base coating (U.S. Pat. No. 6,251,136). Ding et al. teaches a method of applying drug-release polymer coatings that uses solvents (U.S. Pat. No. 5,980,972) wherein the solutions are applied either sequentially or simultaneously onto the devices by spraying or dipping to form a substantially homogenous composite layer of the polymer and the pharmaceutical agent.


Although various exemplary embodiments of the present invention have been disclosed, it will be apparent to those skilled in the art that changes and modifications can be made which will achieve some of the advantages of the invention without departing from the spirit and scope of the invention. It will be apparent to those reasonably skilled in the art that other components performing the same functions may be suitably substituted.

Claims
  • 1. A self-expandable apparatus for removal of a thrombus in a blood vessel, comprising: a tubular structure having a proximal end and a distal end, the structure having (a) a distal portion comprising a first plurality of cells, (b) a proximal portion comprising a second plurality of cells,(c) a first diameter at the distal end, and (d) a second diameter at the proximal end, the distal portion having a distally widening taper at a distal end portion of the distal portion such that the first diameter is greater than the second diameter, the apparatus further comprising a connection point located at a proximal end of the proximal portion wherein the proximal portion converges at the connection point, the apparatus further comprising two edges extending parallel to a longitudinal axis of the structure, wherein the structure is configured to assume an expanded configuration at the place of implantation, and wherein the structure is configured to be modified into a volume-reduced configuration for insertion within a microcatheter, the volume-reduced configuration having a smaller cross-sectional dimension than the expanded configuration, the two edges being overlapped in the volume-reduced configuration, wherein the structure is configured to expand into the thrombus when transitioning from the volume-reduced configuration to the expanded configuration.
  • 2. The apparatus of claim 1, wherein the distal end of the structure comprises radiopaque markers having a spiral or eyelet shape.
  • 3. The apparatus of claim 1, wherein the distal end of the structure is bent and extends distally at an acute angle relative to the longitudinal axis of the structure.
  • 4. The apparatus of claim 1, the structure comprising a first plurality of cells at a proximal portion, a second plurality of cells at a tapered portion, and wherein the distal end of the structure comprises a third plurality of cells and wherein said third plurality of cells has a smaller cell size than the second plurality of cells.
  • 5. The apparatus of claim 1, wherein the distal end of the structure comprises one or more pegs and/or hooks.
  • 6. The apparatus of claim 1, wherein the distal end of the structure further comprises the addition of synthetic fibers.
  • 7. The apparatus of claim 1, wherein the distal end of the structure has been heated for a sufficient time to provide increased radial strength.
  • 8. The apparatus of claim 1, wherein the structure is coated with an anticoagulant or antiplatelet drug.
  • 9. The apparatus of claim 8, wherein the structure is further coated with a biodegradable, biocompatible polymer to provide for sustained release of the anticoagulant or antiplatelet drug.
  • 10. The apparatus of claim 1, wherein the structure comprises reservoirs to hold an anticoagulant or antiplatelet drug.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Phase of International Application No. PCT/US2009/034774, filed on Feb. 20, 2009, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application Ser. No. 61/030,838 filed on Feb. 22, 2008, each of which is hereby incorporated by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2009/034774 2/20/2009 WO 00 11/22/2010
Publishing Document Publishing Date Country Kind
WO2009/105710 8/27/2009 WO A
US Referenced Citations (776)
Number Name Date Kind
2709999 Nagel Jun 1955 A
3174851 Buehler Mar 1965 A
3351463 Rozner Nov 1967 A
3506171 Rupert Apr 1970 A
3753700 Harrison Aug 1973 A
3996938 Clark, III Dec 1976 A
4046150 Schwartz et al. Sep 1977 A
4299255 Miller Nov 1981 A
4347846 Dormia Sep 1982 A
4403612 Fogarty Sep 1983 A
4611594 Grayhack et al. Sep 1986 A
4612931 Dormia Sep 1986 A
4650466 Luther Mar 1987 A
4655771 Wallsten Apr 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4793348 Palmaz Dec 1988 A
4890611 Monfort et al. Jan 1990 A
4993481 Kamimoto Feb 1991 A
4998539 Delsanti Mar 1991 A
5035686 Crittenden Jul 1991 A
5057114 Wittich Oct 1991 A
5071407 Termin et al. Dec 1991 A
5100423 Fearnot Mar 1992 A
5102417 Palmaz Apr 1992 A
5190058 Jones et al. Mar 1993 A
5192286 Phan et al. Mar 1993 A
5195984 Schatz Mar 1993 A
5197978 Hess Mar 1993 A
5217484 Marks Jun 1993 A
5222964 Cooper Jun 1993 A
5222971 Willard et al. Jun 1993 A
5275622 Lazarus Jan 1994 A
5312344 Grinfeld et al. May 1994 A
5327885 Griffith Jul 1994 A
5330482 Gibbs et al. Jul 1994 A
5344395 Whalen Sep 1994 A
5354295 Guglielmi et al. Oct 1994 A
5370653 Cragg Dec 1994 A
5411549 Peters May 1995 A
5423829 Pham et al. Jun 1995 A
5425739 Jessen Jun 1995 A
5449372 Schmaltz Sep 1995 A
5456667 Ham et al. Oct 1995 A
5490859 Mische et al. Feb 1996 A
5496330 Bates et al. Mar 1996 A
5501694 Ressemann et al. Mar 1996 A
5527282 Segal Jun 1996 A
5527326 Hermann et al. Jun 1996 A
5540680 Guglielmi et al. Jul 1996 A
5540707 Ressemann et al. Jul 1996 A
5569245 Guglielmi et al. Oct 1996 A
5571122 Kelly et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5624449 Pham et al. Apr 1997 A
5643309 Myler Jul 1997 A
5649906 Gory Jul 1997 A
5653743 Martin Aug 1997 A
5669933 Simon et al. Sep 1997 A
5681336 Clement Oct 1997 A
5683449 Marcade Nov 1997 A
5690667 Gia Nov 1997 A
5695469 Segal Dec 1997 A
5695519 Summers et al. Dec 1997 A
5718724 Goicoechea Feb 1998 A
5720764 Naderlinger Feb 1998 A
5743905 Eder et al. Apr 1998 A
5749883 Halpern May 1998 A
5759192 Saunders Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5792145 Bates et al. Aug 1998 A
5792157 Mische et al. Aug 1998 A
5795322 Boudewijn Aug 1998 A
5800454 Jacobsen et al. Sep 1998 A
5800457 Gelbfish Sep 1998 A
5800519 Sandock Sep 1998 A
5800520 Fogarty et al. Sep 1998 A
5800525 Bachinski et al. Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5824037 Fogarty et al. Oct 1998 A
5827304 Hart Oct 1998 A
5827324 Cassell Oct 1998 A
5836868 Ressemann et al. Nov 1998 A
5848964 Samuels Dec 1998 A
5851206 Guglielmi et al. Dec 1998 A
5853419 Imran Dec 1998 A
5855578 Guglielmi et al. Jan 1999 A
5882329 Patterson et al. Mar 1999 A
5891128 Gia et al. Apr 1999 A
5895385 Guglielmi et al. Apr 1999 A
5895398 Wensel Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5904698 Thomas et al. May 1999 A
5911717 Jacobsen et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5913895 Burpee et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919187 Guglielmi et al. Jul 1999 A
5922019 Hankh Jul 1999 A
5925037 Guglielmi et al. Jul 1999 A
5925061 Ogi et al. Jul 1999 A
5928226 Guglielmi et al. Jul 1999 A
5928260 Chin Jul 1999 A
5935139 Bates Aug 1999 A
5938671 Katoh Aug 1999 A
5938697 Killion Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5941895 Myler Aug 1999 A
5944714 Guglielmi et al. Aug 1999 A
5947962 Guglielmi et al. Sep 1999 A
5947995 Samuels Sep 1999 A
5948016 Jang Sep 1999 A
5951599 McCrory Sep 1999 A
5954743 Jang Sep 1999 A
5961547 Razavi Oct 1999 A
5964797 Ho Oct 1999 A
5968013 Smith Oct 1999 A
5972016 Morales Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5972219 Habets Oct 1999 A
5976120 Chow Nov 1999 A
5976126 Guglielmi Nov 1999 A
5976131 Guglielmi et al. Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5984929 Bashiri et al. Nov 1999 A
6001118 Daniel Dec 1999 A
6010449 Selmon Jan 2000 A
6010498 Guglielmi Jan 2000 A
6010521 Lee Jan 2000 A
6013093 Nott et al. Jan 2000 A
6015424 Rosenbluth Jan 2000 A
6039721 Johnson Mar 2000 A
6051020 Goicoechea Apr 2000 A
6059814 Ladd May 2000 A
6063070 Eder May 2000 A
6063100 Diaz et al. May 2000 A
6063104 Villar May 2000 A
6063111 Hieshima et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson et al. May 2000 A
6077260 Wheelock et al. Jun 2000 A
6083220 Guglielmi et al. Jul 2000 A
6093199 Brown Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096053 Bates Aug 2000 A
6099549 Bosma et al. Aug 2000 A
6106548 Roubin Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6117167 Goicoechea Sep 2000 A
6118001 Owen et al. Sep 2000 A
6123115 Greenhalgh Sep 2000 A
6123714 Gia et al. Sep 2000 A
6129755 Mathis et al. Oct 2000 A
6136006 Johnson Oct 2000 A
6146396 Konya et al. Nov 2000 A
6156061 Wallace et al. Dec 2000 A
6159238 Killion Dec 2000 A
6159239 Greenhalgh Dec 2000 A
6164339 Greenhalgh Dec 2000 A
6165178 Bashiri et al. Dec 2000 A
6165213 Goicoechea et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168603 Leslie et al. Jan 2001 B1
6168604 Cano Jan 2001 B1
6179857 Diaz et al. Jan 2001 B1
6187017 Gregory, Jr. Feb 2001 B1
6190358 Fitzmaurice Feb 2001 B1
6190394 Lind et al. Feb 2001 B1
6192944 Greenhalgh Feb 2001 B1
6193708 Ken Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6203552 Bagley et al. Mar 2001 B1
6210364 Anderson Apr 2001 B1
6214025 Thistle et al. Apr 2001 B1
6217609 Haverkost Apr 2001 B1
6221096 Aiba Apr 2001 B1
6231598 Berry May 2001 B1
6238412 Dubrul et al. May 2001 B1
6238430 Klumb May 2001 B1
6241746 Bosma et al. Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6254571 Hart Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6264686 Rieu et al. Jul 2001 B1
6264687 Tomonto Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6273900 Nott et al. Aug 2001 B1
6277125 Barry et al. Aug 2001 B1
6277126 Barry et al. Aug 2001 B1
6280413 Clark Aug 2001 B1
6283940 Mulholland Sep 2001 B1
6283992 Hankh Sep 2001 B1
6290720 Khosravi Sep 2001 B1
6302906 Goicoechea Oct 2001 B1
6305436 Andersen Oct 2001 B1
6306141 Jervis Oct 2001 B1
6312463 Rourke et al. Nov 2001 B1
6322585 Khosravi Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6325820 Khosravi Dec 2001 B1
6325822 Chouinard Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6371969 Tsugita et al. Apr 2002 B1
6379329 Naglreiter et al. Apr 2002 B1
6383205 Samson et al. May 2002 B1
6390993 Cornish May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6409721 Wheelock et al. Jun 2002 B1
6425893 Guglielmi Jul 2002 B1
6425914 Wallace et al. Jul 2002 B1
6428558 Jones et al. Aug 2002 B1
6432122 Gilson et al. Aug 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443972 Bosma et al. Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6454780 Wallace Sep 2002 B1
6458139 Palmer et al. Oct 2002 B1
6468266 Bashiri et al. Oct 2002 B1
6468301 Amplatz Oct 2002 B1
6475236 Roubin Nov 2002 B1
6475237 Drasler Nov 2002 B2
6485500 Kokish Nov 2002 B1
6485509 Killion Nov 2002 B2
6485524 Strecker Nov 2002 B2
6491719 Fogarty et al. Dec 2002 B1
6500182 Foster Dec 2002 B2
6514273 Voss et al. Feb 2003 B1
6520968 Bates et al. Feb 2003 B2
6530935 Wensel et al. Mar 2003 B2
6533811 Ryan et al. Mar 2003 B1
6537294 Boyle Mar 2003 B1
6551341 Boylan Apr 2003 B2
6551342 Shen et al. Apr 2003 B1
6553810 Webb Apr 2003 B2
6554842 Heuser et al. Apr 2003 B2
6554849 Jones et al. Apr 2003 B1
6554856 Doorly Apr 2003 B1
6558405 McInnes May 2003 B1
6562066 Martin May 2003 B1
6569179 Teoh May 2003 B2
6569193 Cox May 2003 B1
6572648 Klumb et al. Jun 2003 B1
6575997 Palmer et al. Jun 2003 B1
6589230 Gia et al. Jul 2003 B2
6589236 Wheelock et al. Jul 2003 B2
6589265 Palmer Jul 2003 B1
6592607 Palmer et al. Jul 2003 B1
6592615 Marcade Jul 2003 B1
6605057 Fitzmaurice Aug 2003 B2
6610077 Hancock Aug 2003 B1
6616617 Ferrera Sep 2003 B1
6620152 Guglielmi Sep 2003 B2
6629953 Boyd Oct 2003 B1
6632241 Hancock Oct 2003 B1
6635081 Khosravi Oct 2003 B2
6638294 Palmer Oct 2003 B1
6641590 Palmer et al. Nov 2003 B1
6645224 Gilson et al. Nov 2003 B2
6652505 Tsugita Nov 2003 B1
6652548 Evans et al. Nov 2003 B2
6652576 Stalker Nov 2003 B1
6656214 Fogarty et al. Dec 2003 B1
6660014 Demarais et al. Dec 2003 B2
6660021 Palmer et al. Dec 2003 B1
6663607 Slaikeu Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6666829 Cornish Dec 2003 B2
6669723 Killion Dec 2003 B2
6673025 Richardson Jan 2004 B1
6673106 Mitelberg et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6685722 Rosenbluth Feb 2004 B1
6685738 Chouinard Feb 2004 B2
6692508 Wensel et al. Feb 2004 B2
6695813 Boyle Feb 2004 B1
6702782 Miller et al. Mar 2004 B2
6702843 Brown Mar 2004 B1
6709440 Callol Mar 2004 B2
6716178 Kilpatrick Apr 2004 B1
6716238 Elliott Apr 2004 B2
6723108 Jones et al. Apr 2004 B1
6723112 Ho Apr 2004 B2
6730104 Sepetka May 2004 B1
6733519 Lashinski May 2004 B2
6743236 Barry et al. Jun 2004 B2
6746468 Sepetka Jun 2004 B1
6764506 Roubin Jul 2004 B2
6773454 Wholey Aug 2004 B2
6790237 Stinson Sep 2004 B2
6795979 Fournier Sep 2004 B2
6802851 Jones Oct 2004 B2
6811560 Jones et al. Nov 2004 B2
6818013 Mitelberg et al. Nov 2004 B2
6818015 Hankh Nov 2004 B2
6821291 Bolea Nov 2004 B2
6824558 Parodi Nov 2004 B2
6833002 Stack et al. Dec 2004 B2
6833003 Jones et al. Dec 2004 B2
6840958 Nunez Jan 2005 B2
6878151 Carrison et al. Apr 2005 B2
6881220 Edwin Apr 2005 B2
6887268 Butaric et al. May 2005 B2
6893413 Martin May 2005 B2
6913612 Palmer et al. Jul 2005 B2
6921414 Klumb et al. Jul 2005 B2
6945977 Demarais et al. Sep 2005 B2
6949620 Aida Sep 2005 B2
6953468 Jones et al. Oct 2005 B2
6953472 Palmer Oct 2005 B2
6955685 Escamilla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6960228 Mitelberg et al. Nov 2005 B2
6974473 Barclay et al. Dec 2005 B2
6989020 Jones et al. Jan 2006 B2
6991641 Diaz Jan 2006 B2
6994723 McMahon Feb 2006 B1
7001422 Escamilla et al. Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7004955 Shen Feb 2006 B2
7004956 Palmer et al. Feb 2006 B2
7018401 Hyodoh Mar 2006 B1
7029688 Hubbell Apr 2006 B2
7037329 Martin May 2006 B2
7037331 Mitelberg et al. May 2006 B2
7041116 Goto et al. May 2006 B2
7048014 Hyodoh May 2006 B2
7052500 Bashiri et al. May 2006 B2
7056328 Arnott Jun 2006 B2
7056336 Armstrong Jun 2006 B2
7058456 Pierce Jun 2006 B2
7060091 Killion Jun 2006 B2
7089218 Visel Aug 2006 B1
7097653 Freudenthal et al. Aug 2006 B2
7101380 Khachin et al. Sep 2006 B2
7112217 Kugler Sep 2006 B1
7118600 Dua Oct 2006 B2
7125419 Sequin Oct 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7128736 Abrams Oct 2006 B1
7144421 Carpenter Dec 2006 B2
7147655 Chermoni Dec 2006 B2
7147659 Jones Dec 2006 B2
7147660 Chobotov Dec 2006 B2
7156869 Pacetti Jan 2007 B1
7156871 Jones et al. Jan 2007 B2
7160317 Mc Hale Jan 2007 B2
7169165 Belef Jan 2007 B2
7172575 El-Nounou Feb 2007 B2
7172617 Colgan Feb 2007 B2
7175607 Lim Feb 2007 B2
7179273 Palmer et al. Feb 2007 B1
7179276 Barry et al. Feb 2007 B2
7179284 Khosravi Feb 2007 B2
7182774 Barry et al. Feb 2007 B2
7195648 Jones et al. Mar 2007 B2
7201769 Jones et al. Apr 2007 B2
7201770 Johnson Apr 2007 B2
7223284 Khosravi May 2007 B2
7232432 Fulton, III et al. Jun 2007 B2
7238197 Sequin Jul 2007 B2
7240516 Pryor Jul 2007 B2
7241301 Thramann Jul 2007 B2
7264628 Jones et al. Sep 2007 B2
7270674 Jones et al. Sep 2007 B2
7279003 Berra Oct 2007 B2
7279292 Imam Oct 2007 B2
7285126 Sepetka et al. Oct 2007 B2
7294123 Jones et al. Nov 2007 B2
7294147 Hartley Nov 2007 B2
7300458 Henkes et al. Nov 2007 B2
7303572 Melsheimer Dec 2007 B2
7306619 Palmer Dec 2007 B1
7306622 Jones et al. Dec 2007 B2
7309345 Wallace Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7311726 Mitelberg et al. Dec 2007 B2
7323000 Monstdt et al. Jan 2008 B2
7323005 Wallace Jan 2008 B2
7323006 Andreas Jan 2008 B2
7326240 Caro Feb 2008 B1
7344550 Carrison et al. Mar 2008 B2
7344556 Seguin Mar 2008 B2
7344558 Lorenzo et al. Mar 2008 B2
7351255 Andreas Apr 2008 B2
7354455 Stinson Apr 2008 B2
7357809 Jones et al. Apr 2008 B2
7367987 Balgobin et al. May 2008 B2
7371251 Mitelberg et al. May 2008 B2
7371252 Balgobin et al. May 2008 B2
7377932 Mitelberg et al. May 2008 B2
7402169 Killion Jul 2008 B2
7407509 Greenberg Aug 2008 B2
7435254 Chouinard Oct 2008 B2
7438720 Shaked Oct 2008 B2
7455646 Richardson Nov 2008 B2
7473272 Pryor Jan 2009 B2
7481821 Fogarty et al. Jan 2009 B2
7485122 Teoh Feb 2009 B2
7494474 Richardson Feb 2009 B2
7510565 Gilson et al. Mar 2009 B2
7517352 Evans et al. Apr 2009 B2
7524319 Dubrul Apr 2009 B2
7534252 Sepetka et al. May 2009 B2
7549974 Nayak Jun 2009 B2
7553314 Khachin et al. Jun 2009 B2
7553321 Litzenberg et al. Jun 2009 B2
7582101 Jones et al. Sep 2009 B2
7640952 Khachin et al. Jan 2010 B2
7691122 Dieck Apr 2010 B2
7727242 Sepetka Jun 2010 B2
7727243 Sepetka Jun 2010 B2
7749243 Phung Jul 2010 B2
7780694 Palmer et al. Aug 2010 B2
7833240 Okushi Nov 2010 B2
7972342 Gandhi Jul 2011 B2
7976560 Denison Jul 2011 B2
8052640 Fiorella Nov 2011 B2
8062307 Sepetka Nov 2011 B2
8066757 Ferrera Nov 2011 B2
8070791 Ferrera Dec 2011 B2
8088140 Ferrera Jan 2012 B2
8100918 Gandhi Jan 2012 B2
8100935 Rosenbluth Jan 2012 B2
8105333 Sepetka Jan 2012 B2
8357179 Grandfield et al. Jan 2013 B2
20010000797 Mazzocchi May 2001 A1
20010004705 Killion Jun 2001 A1
20010010013 Cox Jul 2001 A1
20010031981 Evans Oct 2001 A1
20010034531 Ho Oct 2001 A1
20010041899 Foster Nov 2001 A1
20010044633 Klint Nov 2001 A1
20010044647 Pinchuk Nov 2001 A1
20010044649 Vallana et al. Nov 2001 A1
20010047202 Slaikeu Nov 2001 A1
20010051823 Khosravi Dec 2001 A1
20010053929 Vonesh et al. Dec 2001 A1
20020004681 Teoh Jan 2002 A1
20020007210 Chouinard Jan 2002 A1
20020016564 Courtney Feb 2002 A1
20020016624 Patterson Feb 2002 A1
20020032479 Hankh Mar 2002 A1
20020038142 Khosravi Mar 2002 A1
20020038146 Harry Mar 2002 A1
20020052643 Wholey May 2002 A1
20020068968 Hupp Jun 2002 A1
20020072790 McGuckin Jun 2002 A1
20020087209 Edwin Jul 2002 A1
20020091355 Hayden Jul 2002 A1
20020095141 Belef Jul 2002 A1
20020143387 Soetikno Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020169458 Connors, III Nov 2002 A1
20020183831 Rolando Dec 2002 A1
20020193868 Mitelberg et al. Dec 2002 A1
20020198588 Armstrong Dec 2002 A1
20030004536 Boylan Jan 2003 A1
20030023230 Lewis Jan 2003 A1
20030023299 Amplatz Jan 2003 A1
20030032941 Boyle Feb 2003 A1
20030032977 Brady Feb 2003 A1
20030040771 Hyodoh Feb 2003 A1
20030040772 Hyodoh Feb 2003 A1
20030055440 Jones Mar 2003 A1
20030055451 Jones Mar 2003 A1
20030074056 Killion Apr 2003 A1
20030078605 Bashiri Apr 2003 A1
20030097114 Ouriel May 2003 A1
20030105484 Boyle Jun 2003 A1
20030125791 Sequin Jul 2003 A1
20030125798 Martin Jul 2003 A1
20030130719 Martin Jul 2003 A1
20030139796 Sequin Jul 2003 A1
20030139803 Sequin Jul 2003 A1
20030149475 Hyodoh Aug 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030176914 Rabkin Sep 2003 A1
20030199921 Palmer Oct 2003 A1
20030204202 Palmer Oct 2003 A1
20040002752 Griffin Jan 2004 A1
20040006306 Evans Jan 2004 A1
20040006381 Sequin Jan 2004 A1
20040010308 Zafrir-Pachter et al. Jan 2004 A1
20040019322 Hoffmann Jan 2004 A1
20040026942 Kessler Feb 2004 A1
20040030378 Khosravi Feb 2004 A1
20040034386 Fulton Feb 2004 A1
20040049258 Khosravi Mar 2004 A1
20040054367 Jimenez Mar 2004 A1
20040059259 Cornish Mar 2004 A1
20040059407 Escamilla et al. Mar 2004 A1
20040068288 Palmer Apr 2004 A1
20040073300 Chouinard Apr 2004 A1
20040078050 Monstadt et al. Apr 2004 A1
20040078071 Escamilla Apr 2004 A1
20040079429 Miller Apr 2004 A1
20040088002 Boyle May 2004 A1
20040098025 Sepetka et al. May 2004 A1
20040102838 Killion May 2004 A1
20040106979 Goicoechea Jun 2004 A1
20040114912 Okamoto Jun 2004 A1
20040117003 Ouriel Jun 2004 A1
20040147939 Rabkin Jul 2004 A1
20040153117 Clubb Aug 2004 A1
20040158307 Jones Aug 2004 A1
20040158312 Chouinard Aug 2004 A1
20040186562 Cox Sep 2004 A1
20040193246 Ferrera Sep 2004 A1
20040199201 Kellett Oct 2004 A1
20040215312 Andreas Oct 2004 A1
20040215319 Berra Oct 2004 A1
20040249439 Richter Dec 2004 A1
20040254628 Nazzaro Dec 2004 A1
20040260385 Jones Dec 2004 A1
20050021125 Stack et al. Jan 2005 A1
20050033334 Santra Feb 2005 A1
20050033348 Sepetka et al. Feb 2005 A1
20050033349 Jones Feb 2005 A1
20050033409 Burke Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050038468 Panetta Feb 2005 A1
20050038496 Jones Feb 2005 A1
20050049676 Nazzaro Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050060017 Fischell Mar 2005 A1
20050075715 Borges Apr 2005 A1
20050080480 Bolea Apr 2005 A1
20050090857 Kusleika Apr 2005 A1
20050090888 Hines Apr 2005 A1
20050096726 Sequin May 2005 A1
20050102018 Carpenter May 2005 A1
20050107823 Leone May 2005 A1
20050119684 Guterman Jun 2005 A1
20050125023 Bates Jun 2005 A1
20050126979 Lowe Jun 2005 A1
20050131515 Cully Jun 2005 A1
20050131516 Greenhalgh Jun 2005 A1
20050159774 Belef Jul 2005 A1
20050165441 McGuckin et al. Jul 2005 A1
20050177228 Solem Aug 2005 A1
20050187612 Edwin Aug 2005 A1
20050192661 Griffen Sep 2005 A1
20050209673 Shaked Sep 2005 A1
20050209675 Ton Sep 2005 A1
20050209678 Henkes et al. Sep 2005 A1
20050216050 Sepetka Sep 2005 A1
20050222583 Cano Oct 2005 A1
20050222607 Palmer Oct 2005 A1
20050222676 Shanley et al. Oct 2005 A1
20050267570 Shadduck Dec 2005 A1
20050277978 Greenhalgh Dec 2005 A1
20060020285 Niermann Jan 2006 A1
20060020321 Parker Jan 2006 A1
20060025845 Escamilla Feb 2006 A1
20060025850 Feller Feb 2006 A1
20060030865 Balg Feb 2006 A1
20060036281 Patterson Feb 2006 A1
20060052797 Kanamaru Mar 2006 A1
20060052816 Bates Mar 2006 A1
20060058833 VanCamp Mar 2006 A1
20060058836 Bose Mar 2006 A1
20060058838 Bose Mar 2006 A1
20060074480 Bales Apr 2006 A1
20060089703 Escamilla Apr 2006 A1
20060100663 Palmer May 2006 A1
20060106421 Teoh May 2006 A1
20060106448 Shaked May 2006 A1
20060122643 Wasicek Jun 2006 A1
20060122685 Bonsignore Jun 2006 A1
20060135947 Soltesz Jun 2006 A1
20060142841 Khosravi Jun 2006 A1
20060142849 Killion Jun 2006 A1
20060195172 Luo Aug 2006 A1
20060200048 Furst Sep 2006 A1
20060200221 Malewicz Sep 2006 A1
20060224179 Kucharczyk et al. Oct 2006 A1
20060224180 Anderson Oct 2006 A1
20060229645 Bonnette Oct 2006 A1
20060259119 Rucker Nov 2006 A1
20060265054 Greenhalgh Nov 2006 A1
20060271090 Shaked Nov 2006 A1
20060276883 Greenberg Dec 2006 A1
20060287701 Pal Dec 2006 A1
20060287704 Hartley Dec 2006 A1
20070032852 Machek Feb 2007 A1
20070043424 Pryor Feb 2007 A1
20070043425 Hartley Feb 2007 A1
20070055299 Ishimaru Mar 2007 A1
20070055358 Krolik Mar 2007 A1
20070055360 Hanson Mar 2007 A1
20070055365 Greenberg Mar 2007 A1
20070067011 Krolik Mar 2007 A1
20070073376 Krolik Mar 2007 A1
20070088387 Eskridge Apr 2007 A1
20070100425 Sequin May 2007 A1
20070118205 Davidson May 2007 A1
20070123972 Greenberg May 2007 A1
20070135826 Zaver Jun 2007 A1
20070135888 Khosravi Jun 2007 A1
20070141036 Gorrochategui Jun 2007 A1
20070142896 Anderson Jun 2007 A1
20070156170 Hancock Jul 2007 A1
20070156228 Majercak Jul 2007 A1
20070162109 Davila Jul 2007 A1
20070179513 Deutsch Aug 2007 A1
20070185501 Martin et al. Aug 2007 A1
20070191866 Palmer Aug 2007 A1
20070191884 Eskridge Aug 2007 A1
20070191924 Rudakov Aug 2007 A1
20070198028 Miloslavski Aug 2007 A1
20070198029 Martin et al. Aug 2007 A1
20070198030 Martin Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070203452 Mehta Aug 2007 A1
20070203559 Freudenthal Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208371 French et al. Sep 2007 A1
20070219621 Hartley Sep 2007 A1
20070225749 Martin et al. Sep 2007 A1
20070225794 Thramann Sep 2007 A1
20070233236 Pryor Oct 2007 A1
20070250040 Provost Oct 2007 A1
20070266542 Melsheimer Nov 2007 A1
20070270932 Headley Nov 2007 A1
20070288034 MacCollum Dec 2007 A1
20070288037 Cheng Dec 2007 A1
20070288038 Bimbo Dec 2007 A1
20070288054 Tanaka Dec 2007 A1
20070288080 Maccollum Dec 2007 A1
20070288083 Hines Dec 2007 A1
20070293846 von Oepen Dec 2007 A1
20070299503 Berra Dec 2007 A1
20080001333 Kleine Jan 2008 A1
20080015558 Harlan Jan 2008 A1
20080015682 Majercak Jan 2008 A1
20080033528 Satasiya Feb 2008 A1
20080039926 Majercak Feb 2008 A1
20080039930 Jones Feb 2008 A1
20080045995 Guterman Feb 2008 A1
20080046064 Sequin Feb 2008 A1
20080046072 Laborde Feb 2008 A1
20080051803 Monjtadt Feb 2008 A1
20080058724 Wallace Mar 2008 A1
20080071178 Greenland Mar 2008 A1
20080077175 Palmer Mar 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080082159 Tseng Apr 2008 A1
20080086196 Truckai Apr 2008 A1
20080097495 Feller, III Apr 2008 A1
20080103477 Jones May 2008 A1
20080103585 Monstadt May 2008 A1
20080109063 Hancock May 2008 A1
20080109067 Caro May 2008 A1
20080114439 Ramaiah May 2008 A1
20080114445 Melsheimer May 2008 A1
20080119888 Huffmaster May 2008 A1
20080125855 Henkes et al. May 2008 A1
20080140107 Bei Jun 2008 A1
20080140181 Reynolds Jun 2008 A1
20080147100 Wallace Jun 2008 A1
20080161903 Sequin Jul 2008 A1
20080161936 Feller Jul 2008 A1
20080167708 Molland Jul 2008 A1
20080183185 Miller et al. Jul 2008 A1
20080183198 Sepetka et al. Jul 2008 A1
20080188865 Miller et al. Aug 2008 A1
20080195140 Myla Aug 2008 A1
20080200946 Braun Aug 2008 A1
20080208319 Rabkin Aug 2008 A1
20080221554 O'Connor Sep 2008 A1
20080221600 Dieck Sep 2008 A1
20080221664 Bales Sep 2008 A1
20080221671 Chouinard Sep 2008 A1
20080228216 Strauss Sep 2008 A1
20080234795 Snow Sep 2008 A1
20080243229 Wallace Oct 2008 A1
20080243232 Hegg Oct 2008 A1
20080247943 Lanza Oct 2008 A1
20080249598 Sherry Oct 2008 A1
20080255678 Cully Oct 2008 A1
20080262506 Griffin Oct 2008 A1
20080262528 Martin Oct 2008 A1
20080262532 Martin Oct 2008 A1
20080262592 Jordan Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080269868 Bei Oct 2008 A1
20080275497 Palmer Nov 2008 A1
20080275498 Palmer Nov 2008 A1
20080275536 Zarins Nov 2008 A1
20080281302 Murphy Nov 2008 A1
20080281350 Sepetka Nov 2008 A1
20080281393 Armstrong Nov 2008 A1
20080281397 Killion Nov 2008 A1
20080281403 Kavteladze Nov 2008 A1
20080306503 Que Dec 2008 A1
20080306504 Win Dec 2008 A1
20080312732 Hartley Dec 2008 A1
20080319525 Tieu Dec 2008 A1
20080319533 Lehe Dec 2008 A1
20090018633 Lindquist Jan 2009 A1
20090018634 State Jan 2009 A1
20090018640 State Jan 2009 A1
20090024157 Anukhin Jan 2009 A1
20090025820 Adams Jan 2009 A1
20090030502 Sun Jan 2009 A1
20090036968 Hepworth Feb 2009 A1
20090036977 Rassat Feb 2009 A1
20090062726 Ford Mar 2009 A1
20090062773 Cornish Mar 2009 A1
20090062834 Moftakhar Mar 2009 A1
20090068097 Sevrain Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090069836 Labdag Mar 2009 A1
20090076450 Caizza Mar 2009 A1
20090082800 Janardhan Mar 2009 A1
20090093822 Ducharme Apr 2009 A1
20090105644 Leonard Apr 2009 A1
20090105722 Fulkerson Apr 2009 A1
20090105737 Fulkerson Apr 2009 A1
20090105747 Chanduszko Apr 2009 A1
20090125053 Ferrera May 2009 A1
20090163851 Holloway et al. Jun 2009 A1
20090192455 Ferrera Jul 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090292297 Ferrere Nov 2009 A1
20090299393 Martin Dec 2009 A1
20100022951 Ferrera Jan 2010 A1
20100100106 Ferrera Apr 2010 A1
20100114017 Lenker May 2010 A1
20100114135 Wilson May 2010 A1
20100137892 Krolik Jun 2010 A1
20100152766 Dieck Jun 2010 A1
20100174309 Fulkerson Jul 2010 A1
20100217187 Fulkerson Aug 2010 A1
20100256600 Ferrera Oct 2010 A1
20100299911 Gianotti Dec 2010 A1
20100318097 Ferrera Dec 2010 A1
20110009875 Grandfield Jan 2011 A1
20110009941 Grandfield Jan 2011 A1
20110152920 Eckhouse Jun 2011 A1
20110160742 Ferrera Jun 2011 A1
20110160757 Ferrera Jun 2011 A1
20110160760 Ferrera Jun 2011 A1
20110160761 Ferrera Jun 2011 A1
20110160763 Ferrera Jun 2011 A1
20110166586 Sepetka Jul 2011 A1
20110172699 Miller Jul 2011 A1
20110184456 Grandfield Jul 2011 A1
20110190797 Fulkerson Aug 2011 A1
20110202088 Eckhouse Aug 2011 A1
20110238106 Ferrera Sep 2011 A1
20110270178 Fiorella Nov 2011 A1
20110288572 Martin Nov 2011 A1
20110301686 Bowman Dec 2011 A1
20110319917 Ferrera Dec 2011 A1
20120016396 Dehnad Jan 2012 A1
20120016406 Ferrera Jan 2012 A1
20120022576 Ferrera Jan 2012 A1
20120022581 Wilson Jan 2012 A1
20120035648 Wilson Feb 2012 A1
20120041411 Horton Feb 2012 A1
20120041449 Eckhouse Feb 2012 A1
20120041459 Fiorella Feb 2012 A1
20120041460 Ferrera Feb 2012 A1
20120041464 Monetti Feb 2012 A1
20120041474 Eckhouse Feb 2012 A1
20120041475 Ferrera Feb 2012 A1
20120046686 Wilson Feb 2012 A1
20120065660 Ferrera Mar 2012 A1
20120071964 Cattaneo Mar 2012 A1
20120078140 Nita Mar 2012 A1
20120078285 Griffin Mar 2012 A1
20120089216 Rapaport Apr 2012 A1
20120116443 Ferrera May 2012 A1
Foreign Referenced Citations (121)
Number Date Country
9604566-3 Sep 1998 BR
2389374 May 2001 CA
2804058 Aug 1978 DE
2821048 Nov 1979 DE
8435489 Aug 1986 DE
19703482 Aug 1998 DE
10010840 Sep 2001 DE
201466 Nov 1986 EP
321912 Dec 1988 EP
484468 May 1992 EP
629125 Dec 1994 EP
707830 Apr 1996 EP
719522 Jul 1996 EP
726745 Aug 1996 EP
737450 Oct 1996 EP
739606 Oct 1996 EP
750886 Jan 1997 EP
752236 Jan 1997 EP
800790 Oct 1997 EP
803230 Oct 1997 EP
804904 Nov 1997 EP
804905 Nov 1997 EP
804906 Nov 1997 EP
807410 Nov 1997 EP
820729 Jan 1998 EP
826341 Mar 1998 EP
826342 Mar 1998 EP
832606 Apr 1998 EP
861634 Sep 1998 EP
914803 May 1999 EP
964659 Dec 1999 EP
1000590 May 2000 EP
1005837 Jun 2000 EP
1009295 Jun 2000 EP
1009296 Jun 2000 EP
1225844 Jul 2002 EP
1266639 Dec 2002 EP
1266640 Dec 2002 EP
1323385 Jul 2003 EP
1329196 Jul 2003 EP
1351626 Oct 2003 EP
1366720 Dec 2003 EP
1400219 Mar 2004 EP
1437097 Jul 2004 EP
2257248 Oct 2011 EP
2301450 Nov 2011 EP
2417919 Feb 2012 EP
2343488 Oct 1977 FR
2020557 Nov 1979 GB
2-95359 Apr 1990 JP
02255157 Oct 1990 JP
6-246004 Sep 1994 JP
8-033719 Feb 1996 JP
2975584 Nov 1999 JP
2001-190686 Jul 2001 JP
2001178830 Jul 2001 JP
2003-033359 Feb 2003 JP
2006-075233 Mar 2006 JP
2006-094876 Apr 2006 JP
2007-185363 Jul 2007 JP
2007-222658 Sep 2007 JP
2007-236471 Sep 2007 JP
WO 9403127 Feb 1994 WO
WO-9617634 Jun 1996 WO
WO-9628116 Sep 1996 WO
WO-9704711 Feb 1997 WO
WO-9825656 Oct 1998 WO
WO 9855173 Dec 1998 WO
WO-9855175 Dec 1998 WO
WO-9916382 Apr 1999 WO
WO-9923976 May 1999 WO
WO-9925252 May 1999 WO
WO-9929264 Jun 1999 WO
WO-9944542 Sep 1999 WO
WO-9948429 Sep 1999 WO
WO-9948440 Sep 1999 WO
WO-0012166 Mar 2000 WO
WO 0032265 Jun 2000 WO
WO 0053120 Sep 2000 WO
WO-0059405 Oct 2000 WO
WO 0108743 Feb 2001 WO
WO 0134041 May 2001 WO
WO 0136034 May 2001 WO
WO-0132099 May 2001 WO
WO 0145569 Jun 2001 WO
WO-0145566 Jun 2001 WO
WO-0172240 Oct 2001 WO
WO-0193780 Dec 2001 WO
WO-02054980 Jul 2002 WO
WO 03011188 Feb 2003 WO
WO 03017823 Mar 2003 WO
WO-2004008991 Jan 2004 WO
WO 2004093696 Nov 2004 WO
WO 2006052439 May 2006 WO
WO 2007089897 Aug 2007 WO
WO 2007121005 Oct 2007 WO
WO-2008063156 May 2008 WO
WO 2008117256 Oct 2008 WO
WO 2008117257 Oct 2008 WO
WO 2008124728 Oct 2008 WO
WO-2009105710 Aug 2009 WO
WO 2009124288 Oct 2009 WO
WO 2009126747 Oct 2009 WO
WO 2010010545 Jan 2010 WO
WO 2010023671 Mar 2010 WO
WO 2010046897 Apr 2010 WO
WO 2010049121 May 2010 WO
WO 2010062363 Jun 2010 WO
WO 2010102307 Sep 2010 WO
WO 2010115642 Oct 2010 WO
WO 2010121037 Oct 2010 WO
WO 2010121049 Oct 2010 WO
WO 2011054531 May 2011 WO
WO 2011095352 Aug 2011 WO
WO 2011133486 Oct 2011 WO
WO 2011135556 Nov 2011 WO
WO 2011144336 Nov 2011 WO
WO 2011147567 Dec 2011 WO
WO 2012009675 Jan 2012 WO
WO 2012025245 Mar 2012 WO
WO 2012025247 Mar 2012 WO
Non-Patent Literature Citations (25)
Entry
US 6,056,761, 5/2000, Gia et al. (withdrawn).
Henkes, H., et al., “A Novel Microcatheter—Delivered, Highly-Flexible and Fully-Retrievable Stent, Specifically Designed for Intracranial Use”, Interventional Neuroradiolog, vol. 9, pp. 391-393, 2003.
E.I. Levy et al., Self-Expanding Stents for Recanalization of Acute Cerebrovascular Occulsions; AJNR May 28, 2007.
Schumacher, H., “Endovascular Mechanical Thrombectomy of an Occluded Superior Division Branch of the Left MCA for Acute Cardioembolic Stroke,” Cardiovascular and Interventional Radiology, Jun. 2003 26(3) pp. 305-308.
Nesbit, G., “New and Future Endovascular Treatment Strategies for Acute Ischemic Stroke,” Journal of Vascular and Interventional Radiology, Jan. 2004 15(1) pp. S103-S110.
Imai, K., “Clot Removal Therapy by Aspiration and Extraction for Acute Embolic Carotid Occlusion,” American Journal of Neuroradiology, Aug. 2006, vol. 27, pp. 1521-1527.
Wildberger, J., “Percutaneous Venous Thrombectomy Using the Arrow-Trerotola Percutaneous Thrombolytic Device (PTD) with Temporary Caval Filtration: In Vitro Investigations,” Cardiovascular and Interventional Radiology, Mar. 2005 28(2) pp. 221-227.
Castano, C., “Use of the New Solitaire (TM) AB Device for Mechanical Thrombectomy when Merci Clot Retriever Has Failed to Remove the Clot. A Case Report.,” Interventional Neuroradiology, Jul. 2009 15(2) pp. 209-214.
ev3 Solitaire Brochure R2 dated Jan. 12, 2009.
ev3 Solitaire AB Instructions for Use (IFU) dated Dec. 2007. The first commercial sale of the products numbered SAB-4-15 and SAB 4 20, referenced in the ev3 Solitaire AB IFU dated Dec. 2007 occurred on Jan. 4, 2008.
U.S. Appl. No. 60/987,384, filed Nov. 12, 2007.
“Penumbra, Inc. Enrolls First Patients in PULSE Clinical Trial to Evaluate a Fully Retrievable, Dense Mesh Temporary Stent for Immediate Flow Restoration in Interventional Acute Ischemic Stroke Treatment,” Business Wire, Nov. 1, 2010, <http://www.businesswire.com/news/home/d0101101006991/en/Penumbra-Enrolls-Patients-PULSE-Clinical-Trial-Evaluate>.
Doerfler, et al., “A Novel Flexible, Retrievable Endovascular Stent System for Small-Vessel Anatomy: Preliminary in Vivo Data,” Am. J. Neuroradiol. vol. 26, pp. 862-868 (Apr. 2005).
Duerig, et al. An Overview of Superelastic Stent Design. Min. Invas Ther & Allied Technol 2000: 9(3/4) 235-246.
Kelly, et al., Recanalization of an Acute Cerebral Artery Occlusion Using a Self-Expanding, Reconstrainable, Intracranial Microstent as a Temporary Endovascular Bypass; AHA Journal, Jun. 2008 edition.
Lavallee, et al., Stent-Assisted Endovascular Thrombolysis Versus Intravenous Thrombolysis in Internal Carotid Artery Dissection with Tandem Internal Carotid and Middle Cerebral Artery Occlusion, AHA 2007.
Levy, et al., Self-Expanding Stents for Recanalization of Acute Cerebrovascular Occulsions; AJNR May 28, 2007.
Liebig, et al., “A novel self-expanding fully retrievable intracranial stent (SOLO): experience in nine procedures of stent-assisted aneurysm coil occlusion,” Neuroradiology vol. 48, pp. 471-478 (Jul. 2006).
Micro Therapeutics, Inc., DBA EV3 Neurovascular, Inc., Fully deployable. Completely retrievable, Solitaire AB, Neurovascular Remodeling Device. Mar. 2008.
Micro Therapeutics, Inc., DBA EV3 Neurovascular, Inc., Solitaire FR Revascularization Device, Instructions for Use, Rev. Mar. 2009.
Pelz, et al., Advances in Interventional Neuroradiology 2007; American Heart Association Journal, Nov. 2007 edition.
Robertson, Stroke device startup lands National Science Foundation grant, Sacramento Business Journal, Oct. 23, 2009, Sacramento, California.
Sauvegeau, et al. Middle Cerebral Artery Stenting for Acute Ischemic Stroke After Unsuccessful Merci Retrieval; Special Technical Report; Neurosurgery 60:701-706, 2007.
Wakhloo, et al., “Retrievable Closed Cell Intracranial Stent for Foreign Body and Clot Removal,” Neurosurgery, May 5, 2008.
Yavuz, et al., “Immediate and midterm follow-up results of using an electrodetachable, fully retrievable SOLO stent system in the endovascular coil occlusion of wide-necked cerebral aneurysms,” J. Neurosurg. vol. 107, pp. 49-55 (Jul. 2007).
Related Publications (1)
Number Date Country
20110060212 A1 Mar 2011 US
Provisional Applications (1)
Number Date Country
61030838 Feb 2008 US